Updated Jul 16, 2026
Ho William Tai-Wei has filed 1 SEC Form 4 filing across 1 company in the last 90 days.
William Tai-Wei Ho is the President and CEO of IN8bio, Inc., a clinical-stage biopharmaceutical company focused on developing gamma-delta T cell therapies for cancer treatment. His leadership is pivotal in advancing innovative therapies for solid and liquid tumors.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2024-10-08 | INAB | IN8BIO, INC. | A — Grant or award | 126.6K | — |
William Tai-Wei Ho is the President and CEO of IN8bio, Inc., a clinical-stage biopharmaceutical company focused on developing gamma-delta T cell therapies for cancer treatment. His leadership is pivotal in advancing innovative therapies for solid and liquid tumors.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Ho William Tai-Wei profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.